Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
OT-101
Oncotelic Therapeutics
Pancreatic Ductal Adenocarcinoma
1 trial -
OXALIPLATIN, CALCIUM LEVOFOLINATE, FOLINIC ACID, FLUOROURACIL
Ningbo Cancer Hospital
Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery
1 trial -
Obinutuzumab
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
1 trial -
Obinutuzumab
United Therapeutics Europe Ltd
Non-Hodgkin's Lymphoma
1 trial -
Octaplex 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Octaplex 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung
Lacuna Pharma Pty Ltd
Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor
1 trial -
Odronextamab
ADC Therapeutics SA
B-cell Non Hodgkin Lymphoma
1 trial -
Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib
Merck Sharp and Dohme
Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.
1 trial -
Omvoh 300 mg concentrate for solution for infusion, Omvoh 100 mg solution for injection in pre-filled syringe
Eli Lilly Co.
Moderately to Severely Active Ulcerative Colitis
1 trial -
Ondansetron
United Therapeutics Europe Ltd
IBS - Irritable Bowel Syndrome
1 trial -
Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
1 trial -
Ontamalimab
Takeda
Ulcerative Colitis
3 trials -
Open-label rusfertide
Protagonist Therapeutics, Inc
Polycythemia Vera
1 trial -
Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.
United Therapeutics Europe Ltd
Non-Severe Pneumonia
1 trial -
Oral Treprostinil
United Therapeutics Europe Ltd
Pulmonary Hypertension Associated With Sickle Cell Disease
1 trial -
Oral Treprostinil
United Therapeutics Europe Ltd
Pulmonary Arterial Hypertension
2 trials -
Oral treprostinil
United Therapeutics Europe Ltd
Pulmonary Hypertension
2 trials -
Oral treprostinil (UT-15C) sustained release tablets
United Therapeutics Europe Ltd
Pulmonary Hypertension
2 trials -
Oral triiodothyronine
Cardiff Oncology
Postoperative; Dysfunction Following Cardiac Surgery
1 trial -
Orforglipron
Eli Lilly and Company
Peripheral Arterial Disease
1 trial -
Orforglipron, Orforglipron, Orforglipron, Placebo to match ly, Orforglipron, Orforglipron, Orforglipron
Eli Lilly Co.
Peripheral Arterial Disease
1 trial -
Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), Otezla 10mg, 20mg, 30 mg film-coated tablets, ZASOCITINIB, Otezla 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279)
Takeda
Moderate to Severe Plaque Psoriasis
1 trial -
Otezla 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279), Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), ZASOCITINIB
Takeda
Moderate to Severe Plaque Psoriasis
1 trial -
Oxandrolone
United Therapeutics Europe Ltd
Trauma Injury
1 trial -
Oxybutinyn Vaginal Ring 4mg
Teva Pharma GmbH
Overactive Bladder
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources